Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 11/20 | 0.54 |
| ▸ | JAK3 | P52333 | 7/20 | 0.48 |
| ▸ | JAK1 | P23458 | 4/20 | 0.44 |
| ▸ | JAK2 | O60674 | 4/20 | 0.43 |
| ▸ | ITK | Q08881 | 1/20 | 0.43 |
| ▸ | ERBB2 | P04626 | 2/20 | 0.42 |
| ▸ | ERBB4 | Q15303 | 1/20 | 0.41 |
| ▸ | TUBB4A | P04350 | 1/20 | 0.41 |
| ▸ | TUBB | P07437 | 1/20 | 0.41 |
| ▸ | TUBA3C | P0DPH7 | 1/20 | 0.41 |
| ▸ | TUBA1B | P68363 | 1/20 | 0.41 |
| ▸ | TUBA4A | P68366 | 1/20 | 0.41 |
| ▸ | TUBB4B | P68371 | 1/20 | 0.41 |
| ▸ | TUBB3 | Q13509 | 1/20 | 0.41 |
| ▸ | TUBB2A | Q13885 | 1/20 | 0.41 |
| ▸ | TUBB8 | Q3ZCM7 | 1/20 | 0.41 |
| ▸ | TUBA3E | Q6PEY2 | 1/20 | 0.41 |
| ▸ | TUBA1A | Q71U36 | 1/20 | 0.41 |
| ▸ | TUBA1C | Q9BQE3 | 1/20 | 0.41 |
| ▸ | TUBB6 | Q9BUF5 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12262368 | 0.84 | JAK3 (0.64) | EGFRJAK3JAK1JAK2ITK | |
| SCHEMBL12262374 | 0.83 | MAP2K7 (0.54) | EGFRERBB2 | |
| SCHEMBL12282888 | 0.79 | EGFR (0.54) | EGFRJAK3ITKERBB2 | |
| SCHEMBL15807915 | 0.77 | TGM2 (0.58) | EGFRJAK3 | |
| SCHEMBL12262344 | 0.76 | EGFR (0.57) | EGFRJAK3ITKERBB2 | |
| SCHEMBL691538 | 0.74 | EGFR (0.79) | EGFRJAK3JAK1JAK2ITK | |
| SCHEMBL27339286 | 0.72 | PRCP (0.49) | EGFRERBB4TUBB4ATUBBTUBA3C | |
| SCHEMBL13883720 | 0.71 | MAP2K7 (0.42) | EGFRJAK3JAK1JAK2ERBB2 | |
| SCHEMBL690075 | 0.71 | EGFR (0.74) | EGFRJAK3JAK1JAK2ITK | |
| SCHEMBL691474 | 0.71 | EGFR (1.00) | EGFRJAK3ITKERBB2ERBB4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8748606-B2 | 4,6-diaminopyrimidines useful as kinase inhibitors | CELGENE AVILOMICS RESEARCH, INC. (US) | 2014-06-10 | — | — | US | disclosed |
| US-8748606-B2 | 4,6-diaminopyrimidines useful as kinase inhibitors | CELGENE AVILOMICS RESEARCH, INC. (US) | 2014-06-10 | — | — | US | disclosed |
| US-20130065892-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | CELGENE AVILOMICS RESEARCH, INC. (US) | 2013-03-14 | — | — | US | disclosed |
| US-20130065892-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | CELGENE AVILOMICS RESEARCH, INC. (US) | 2013-03-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130065892-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | ABCG2, CYP3A43, CYP3A5 | EGFR 1981/4885JAK3 439/4885JAK1 2115/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.